# Perthera

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/perthera

- Industry: Biotechnology
- Headquarters: McLean, US
- Website: www.perthera.com
- Total disclosed funding: $8.7M
- Latest round: Series A (Jun 28, 2016)
- Investors on record: 1

## About

Perthera, Inc. specializes in precision oncology solutions, leveraging an AI-driven platform to enhance cancer treatment outcomes through personalized therapy recommendations for healthcare providers.Founded in 2012 in McLean, US, Perthera, Inc. focuses on optimizing cancer treatment by integrating multi-omic testing and patient data. The company has raised a total of USD 0.75 mn across six deals, with the latest funding round being a VENTURE DEBT round of USD 2.10 mn on January 2, 2019. The current CEOs are Donna Tuths and Gary Gregory.Perthera offers a comprehensive suite of precision oncology solutions designed to enhance cancer treatment outcomes through its AI Precision Oncology Platform. The core product, the Perthera Report®, integrates multi-omic testing results and historical patient data to provide oncologists with ranked therapy options tailored to individual cancer patients. This approach optimizes treatment plans, mitigates ineffective chemotherapy, and improves clinical decision-making efficiency. The company's services cater to hospitals, clinics, and medical oncologists primarily within the United States while expanding into international markets such as Indonesia through strategic partnerships.Perthera generates revenue through its AI-driven oncology solutions, particularly the Perthera Report®, which is utilized by healthcare providers and oncologists for personalized treatment planning. The company operates on a B2B model, partnering with hospitals and clinics that purchase access to its platform and reports, enhancing their clinical workflows and decision-making capabilities. Revenue is also bolstered through partnerships with biopharmaceutical companies and contract research organizations (CROs), facilitating access to proprietary data and enhancing clinical trial matching for patients.Perthera is focused on expanding its product offerings and geographic reach. Recent funding from the VENTURE DEBT round in January 2019 will support the development of new products aimed at further enhancing their precision oncology solutions. The company plans to expand its services into additional international markets, specifically targeting regions beyond the United States. By leveraging strategic partnerships, Perthera aims to facilitate access to its innovative solutions across a broader spectrum of healthcare providers.

## Funding rounds

- Series A, Jun 28, 2016, $8.7M — Pilot Growth Equity

## Investors

- Pilot Growth Equity (https://capitalatlas.ai/funds/pilot-growth-equity) — Series A